Cargando…

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab

Detalles Bibliográficos
Autores principales:	Palmisano, Gerardo, Di Stefani, Alessandro, Cappilli, Simone, Chiricozzi, Andrea, Peris, Ketty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518751/ https://www.ncbi.nlm.nih.gov/pubmed/37881038 http://dx.doi.org/10.1111/srt.13483

Ejemplares similares

Eruptive lentiginosis in resolving psoriatic plaques
por: Micieli, Robert, et al.
Publicado: (2018)

Eruptive lentiginosis in resolving psoriatic plaques
por: Micieli, Robert, et al.
Publicado: (2018)

Generalized Eruptive Lentiginosis in a Healthy Elderly Man
por: Kim, Min Sung, et al.
Publicado: (2014)

Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment()()
por: Garcia-Souto, Fernando
Publicado: (2021)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis
por: Dattola, Annunziata, et al.
Publicado: (2021)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
por: Chiricozzi, Andrea, et al.
Publicado: (2019)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Risankizumab for psoriasis
Publicado: (2020)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study
por: Tassone, Francesco, et al.
Publicado: (2022)

Use of reflectance confocal microscopy to diagnose occult basal cell carcinoma: 2 case reports
por: Cappilli, Simone, et al.
Publicado: (2018)

Isolated Palmoplantar Lentiginosis
por: Alghubaywi, Faisal, et al.
Publicado: (2023)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Eruptive acral lentiginosis following chemotherapy for acute lymphoblastic leukemia: A case series
por: O’Connor, Cathal, et al.
Publicado: (2021)

Correction to: A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
por: Del Regno, Laura, et al.
Publicado: (2022)

A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
por: Del Regno, Laura, et al.
Publicado: (2022)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

Polymorphic Skin Eruption in a Middle-Aged Man: A Quiz
por: CATAPANO, Silvia, et al.
Publicado: (2023)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Orsini, Diego, et al.
Publicado: (2023)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Successful treatment of a refractory pyoderma gangrenosum with risankizumab
por: Burgdorf, Birte, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature
por: María, Pablo Santa, et al.
Publicado: (2017)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Safety and Efficacy of Risankizumab and Infliximab in the Treatment of Plaque Psoriasis: Results From a Direct and Indirect Meta-Analysis
por: Almohideb, Mohammad
Publicado: (2021)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

A case of nail psoriasis improved with treatment by risankizumab
por: AlAjlan, Abdulmajeed, et al.
Publicado: (2022)

Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
por: Fahmy, Lauren M., et al.
Publicado: (2023)

Acute Vesico-Bullous Eruption from Methotrexate Overdose in a Psoriasis Patient
por: Kim, Hee Joo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t2k7p16q071g7s4nskcnft9s9k